In lung cancer, PD-L1/PD-1 inhibitors immunotherapy was recently found to have better overall response and overall survival for patients with tumor expression of over 50% PD-L1 in tumor cells compared to standard chemotherapy2. The gene discussed is CD274; the disease is lung carcinoma.